Apyx Medical Corporation Announces Public Stock Offering
Apyx Medical Corporation (NASDAQ: APYX), known for its innovative advancements in surgical aesthetics, has recently announced the pricing of its underwritten public offering. This offering includes 2,762,431 shares of common stock, priced at $3.62 each. This provides an exciting opportunity for investors looking to engage with talents in the industry.
Details of the Offering
The set price comes before any deductions for underwriting discounts, commissions, and additional offering expenses. Apyx Medical Corporation aims to utilize net proceeds from this offering for general corporate purposes and working capital, enhancing its position within the market.
Underwriting Management
Lucid Capital Markets has taken the helm as the sole book-running manager for this offering. They are tasked with managing the overall strategy to ensure a smooth process, showing their capability and commitment in supporting the company’s growth.
Future Prospects
This strategic move is expected to close shortly, with the timeline targeting November 19, 2025, subject to standard closing conditions. Investors remain optimistic about how this additional capital will bolster Apyx’s ongoing projects and future initiatives.
Innovative Products from Apyx Medical
Apyx Medical is not just about numbers; their commitment to elevating lives is evident through their cutting-edge products. They focus on surgical aesthetics with tools like Renuvion and the AYON Body Contouring System, both of which have substantially impacted the cosmetic surgery landscape.
Renuvion and AYON
Renuvion utilizes Helium Plasma Technology to deliver controlled heat to tissues, providing surgeons a unique edge. The AYON body contouring system is another innovation that integrates various surgical capabilities into a single platform, streamlining procedures and enhancing patient outcomes.
Commitment to Advancement
Apyx Medical Corporation continues to lead through innovation, backed by numerous clinical documents supporting the effectiveness of their products. For patients, this means that the latest technology is readily accessible, ensuring top-tier medical care.
Contact and Investor Information
Investors can connect with Apyx Medical for deeper insights regarding the offering and products via their investor relations contact, Jeremy Feffer of LifeSci Advisors. He can be reached at 212-915-2568 or through email for any inquiries.
Frequently Asked Questions
What is the pricing for the public offering?
The public offering is priced at $3.62 per share of common stock.
Who manages the offering?
Lucid Capital Markets is managing the underwriting for the offering.
When is the anticipated closing date for the offering?
It is expected to close on or about November 19, 2025, pending usual conditions.
What will the proceeds be used for?
The proceeds from the public offering will be aimed at working capital and general corporate purposes.
How can I find more information about Apyx Medical Corporation?
Individuals seeking additional details can visit the Apyx Medical Corporation website for more information on their offerings and innovations.
